Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hiroaki Aoki is active.

Publication


Featured researches published by Hiroaki Aoki.


World Journal of Gastroenterology | 2014

Sentinel lymph node navigation surgery for early stage gastric cancer

Norio Mitsumori; Hiroshi Nimura; Naoto Takahashi; Masahiko Kawamura; Hiroaki Aoki; Atsuo Shida; Nobuo Omura; Katsuhiko Yanaga

We attempted to evaluate the history of sentinel node navigation surgery (SNNS), technical aspects, tracers, and clinical applications of SNNS using Infrared Ray Electronic Endoscopes (IREE) combined with Indocyanine Green (ICG). The sentinel lymph node (SLN) is defined as a first lymph node (LN) which receives cancer cells from a primary tumor. Reports on clinical application of SNNS for gastric cancers started to appear since early 2000s. Two prospective multicenter trials of SNNS for gastric cancer have also been accomplished in Japan. Kitagawa et al reported that the endoscopic dual (dye and radioisotope) tracer method for SN biopsy was confirmed acceptable and effective when applied to the early-stage gastric cancer (EGC). We have previously reported the usefulness of SNNS in gastrointestinal cancer using ICG as a tracer, combined with IREE (Olympus Optical, Tokyo, Japan) to detect SLN. LN metastasis rate of EGC is low. Hence, clinical application of SNNS for EGC might lead us to avoid unnecessary LN dissection, which could preserve the patients quality of life after operation. The most ideal method of SNNS should allow secure and accurate detection of SLN, and real time observation of lymphatic flow during operation.


Hypertension Research | 2011

Prediction of pregnancy-induced hypertension by a shift of blood pressure class according to the JSH 2009 guidelines.

Seung Chik Jwa; Naoko Arata; Naoko Sakamoto; Noriyoshi Watanabe; Hiroaki Aoki; Asako Kurauchi-Mito; Qiu Dongmei; Yukihiro Ohya; Atsuhiro Ichihara; Michihiro Kitagawa

Elevated blood pressure (BP) at early or mid pregnancy is a known risk factor for pregnancy-induced hypertension (PIH). However, the association between BP changes during the first half of pregnancy and subsequent PIH development is unknown. We used changes in maternal BP between 16 and 20 weeks of gestation to evaluate the risk of PIH. A total of 976 pregnant women with BP estimations recorded before 16 weeks and at 20 weeks of gestation participated in this study. BPs were classified by the Japanese Society of Hypertension 2009 Hypertension Treatment Guidelines (JSH 2009). There was a significant trend for future PIH in women whose JSH 2009 BP class increased between 16 and 20 weeks of gestation, and the risk of PIH was highest among women whose BP was Class IV Hypertension (systolic BP⩾140 mm Hg and/or diastolic BP⩾90 mm Hg). The risk of PIH increased in women whose BPs shifted from Classes I Optimal (systolic BP<120 mm Hg and diastolic BP<80 mm Hg) and II Normal (systolic BP 120–129 mm Hg and/or diastolic BP 80–84 mm Hg) before 16 weeks to Class III High-Normal (systolic BP 130–139 mm Hg and/or diastolic BP 85–89 mm Hg) at 20 weeks of gestation. These shifts in BP class were significantly correlated with the risk of PIH after adjustments for variables (P-value for trend <0.05). Within JSH 2009 Classes I, II and III, a shift in BP from a low to a high class between 16 and 20 weeks of gestation predicts the subsequent development of PIH.


Oncology Letters | 2013

Reduced expression of Rho GDP dissociation inhibitor 2 mRNA is associated with lymph node metastasis in gastric carcinoma

Atsuo Shida; Shuichi Fujioka; Naoto Takahashi; Hiroaki Aoki; Tomoyoshi Okamoto; Norio Mitsumori; Nobuo Omura; Katsuhiko Yanaga

Small GTPase proteins, including RhoA, RhoB, RhoC, Rac1 and cdc42, are molecules that have significant roles in linking cell shape and cell cycle progression in cytoskeletal arrangements and mitogenic signaling. Rho GDP dissociation inhibitor 2 (RhoGDI2) has recently been identified as a metastasis suppressor gene in models of bladder cancer. RhoGDI2 has also been identified as a potential regulator of tumorigenesis and cancer progression. The present study aimed to clarify the significance of RhoGDI2 gene expression in gastric carcinoma and to evaluate the outcome of affected patients. A total of 46 pairs of normal mucosa and cancer specimens were obtained from patients who had undergone a gastrectomy for primary gastric carcinoma and were subjected to semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) for RhoGDI2. The expression of RhoGDI2 mRNA was significantly higher in early-stage gastric cancer specimens compared with the normal gastric epithelium samples. By contrast, the depth of the tumor was negatively correlated with RhoGDI2 mRNA expression. In addition, a reduced expression of RhoGDI2 mRNA was associated with venous system invasion and lymph node metastasis. RhoGDI2 mRNA was more frequently expressed in differentiated adenocarcinoma compared with poorly-differentiated adenocarcinoma. Although the statistical significance was not established, RhoGDI2-positive patients tended to have a superior oncological outcome compared with RhoGDI2-negative patients. The reduced expression of RhoGDI2 mRNA in gastric carcinoma is associated with venous system invasion and lymph node metastasis.


Chemotherapy | 2007

Successful Preoperative Chemotherapy with S-1 plus Low-Dose Cisplatin for Advanced Gastric Cancer with Synchronous Liver Metastases: Report of 2 Cases

Naoto Takahashi; Hiroshi Nimura; Hiroaki Aoki; Tomoki Koyama; Norio Mitsumori; Keisuke Aiba; Hideyuki Kashiwagi; Katsuhiko Yanaga

We report 2 cases of advanced gastric cancer with synchronous liver metastases who were successfully downstaged using S-1 plus low-dose cisplatin chemotherapy followed by surgical resection. S-1 was administered orally (80 mg/m2/day) twice daily for 14 consecutive days, and cisplatin (15 mg/m2) was infused over 1 h on days 1 and 8. Successful downstaging of the hepatic metastases was confirmed by imaging analyses; however, neither patient showed a complete response of the primary lesion in the stomach. Toxicities, according to the WHO criteria, were mild. The patients underwent surgical resection within 4 weeks after the last chemotherapy. Postoperatively, they were discharged without complications and received adjuvant chemotherapy. Both patients remained alive and well at 17 and 12 months after surgery, respectively, without recurrence. These cases provide further evidence that S-1 plus low-dose cisplatin chemotherapy enables downstaging of advanced gastric cancer and a subsequent potentially curative resection without serious complications.


Case Reports in Gastroenterology | 2016

A Giant Gastrointestinal Stromal Tumor of the Stomach with Extramural Growth.

Ryosuke Miyazaki; Seiji Arihiro; Eri Hayashi; Takuya Kitahara; Sayumi Oki; Syunsuke Kamba; Daisuke Ide; Nobuhiko Komoike; Kenichi Satoh; Tomohiro Kato; Masayuki Saruta; Hisao Tajiri; Hiroaki Aoki; Nobuo Omura; Norio Mitsumori; Takehiro Mitsuishi; Haruka Yanagisawa; Hiroyuki Takahashi

A 76-year-old man presented to our hospital with abdominal distention and loss of appetite. The 10% of weight lost relative to this patient in 1 month. Abdominal computed tomography and magnetic resonance imaging revealed a giant mass, with a major axis of 23 cm, containing solid components, not involving the upper abdominal organs. Esophagogastroduodenoscopy showed extramural compression from the middle gastric body to the antrum, as well as a normal mucosal surface. These findings were suggestive of a gastrointestinal stromal tumor attached to the anterior wall of the stomach without metastasis or invasion. Partial gastrectomy was performed for tumor resection, and the patient was subsequently treated with adjuvant imatinib. We report a rare case of a large extramural gastrointestinal stromal tumor of the stomach that was larger than 20 cm in diameter and present a pertinent literature review.


Human genome variation | 2018

Novel TFAP2A mutation in a Japanese family with Branchio-oculo-facial syndrome

Taisuke Sato; Osamu Samura; Noriko Kato; Kosuke Taniguchi; Ken Takahashi; Yuki Ito; Hiroaki Aoki; Masahisa Kobayashi; Ohsuke Migita; Aikou Okamoto; Kenichiro Hata

Branchio-oculo-facial syndrome (BOFS) is a rare autosomal dominant disorder characterized by craniofacial, ocular, and ectodermal anomalies. BOFS is caused by mutation of the transcription factor AP2-alpha gene (TFAP2A). We performed detailed genetic analysis of a Japanese family with clinically suspected BOFS and identified a novel missense mutation resulting in a predicted amino-acid substitution in the highly conserved basic DNA-binding domain of TFAP2A (NM_003220.2:c.699A>C).


European Journal of Medical Genetics | 2018

Molecular genetic analysis reveals atypical confined placental mosaicism with a small supernumerary marker chromosome derived from chromosome 18: A clinical report of discordant results from three prenatal tests

Taisuke Sato; Osamu Samura; Tomona Matsuoka; Masaki Yoshida; Hiroaki Aoki; Ohsuke Migita; Aikou Okamoto; Kenichiro Hata

We present a case with discordant results in three prenatal screening methods, with additional genetic analyses. Non-invasive prenatal testing (NIPT) was performed on a 41-year-old Japanese woman at 10 weeks of gestation, and the result was positive for trisomy 18 with high accuracy. Amniocentesis was performed at 16 weeks of gestation. However, the result showed 47,XX,+mar[16]/47,XX,+18[2]. Fetal examination by ultrasound revealed no malformations. After termination of the pregnancy, we performed additional genetic analyses, and confirmed the presence of confined placental mosaicism (CPM). Furthermore, a small supernumerary marker chromosome (sSMC) was detected in fetal cells, which was derived de novo from the centromere of chromosome 18. Single nucleotide polymorphism array analysis revealed that fetal chromosome 18 was inherited with maternal uniparental disomy, with a relatively large copy-neutral loss of heterozygosity, including its centromere. Our genetic analyses strongly indicated the cause of result discrepancy in prenatal testing as incomplete trisomy 18 rescue leading to atypical CPM with a sSMC. These findings also offer insight into the mechanisms by which chromosomal aberrations form during human oogenesis and embryogenesis.


Case Reports in Obstetrics and Gynecology | 2018

Characterization of a Small Supernumerary Marker Chromosome Derived from Xq28 and 14q11.2 Detected Prenatally

Akihiro Hasegawa; Osamu Samura; Taisuke Sato; Tomona Matsuoka; Yuki Ito; Kazuhiro Kajiwara; Hiroaki Aoki; Yuka Inage; Masahisa Kobayashi; Aikou Okamoto

We present the characterization of a case with a small supernumerary marker chromosome (sSMC) detected prenatally derived from Xq28 and 14q11.2 maternal translocation. A 33-year-old Japanese woman, primigravida, underwent amniocentesis because of fetal growth restriction and fetal structural abnormality at 30 weeks of gestation. The fetal karyotype was identified as 47,XY,+mar. Additionally, the single nucleotide polymorphism array analysis revealed copy number gains at Xq28 and 14q11.2. A male infant, weighing 1,391 g, was delivered at term by cesarean section. Maternal and paternal karyotypes were 46,X,t(X; 14)(q28; q11) and 46,XY, respectively. These findings indicated that the sSMC might have originated from chromosome disjunction at a ratio of three to one. Here we describe a case with an sSMC derived from Xq28 and 14q11.2. Our findings suggest that this sSMC is most likely pathogenic. The collection of additional cases may be required.


Breastfeeding Medicine | 2018

Low Levels of Amlodipine in Breast Milk and Plasma

Hiroaki Aoki; Naoki Ito; Nahoko Kaniwa; Yoshiro Saito; Yuka Wada; Ken Nakajima; Haruhiko Sago; Atsuko Murashima; Aikou Okamoto; Shinya Ito

OBJECTIVE Few clinical reports have addressed the use of the antihypertensive drug amlodipine during breastfeeding. The objective of this study is to characterize concentration-time profiles of amlodipine in maternal and infant plasma, and milk. MATERIALS AND METHODS Plasma and breast milk samples were obtained from eight nursing mothers and their nine newborn nursing infants (median postnatal age: 6.5 days, range 5-7 days). Participants were recruited from February 2009 to June 2009. Multiple blood and milk samples were obtained from the mothers over a 24 hours dosing interval. The blood of infants was also obtained at before and 8 hours after nursing. Amlodipine concentrations were determined by high-performance liquid chromatography. Relative infant dose (RID) was calculated by dividing the infants dose via milk in mg/kg/day by the maternal dose in mg/kg/day, assuming that a daily intake of milk is 150 mL/kg/day in the infants. RESULTS Maximal amlodipine concentrations in mothers ranged from 4.4 to 14.7 ng/mL in plasma, and 6.5 to 19.7 ng/mL in milk (Average milk/plasma ratio: 1.4). RID was 3.4% of the maternal weight-adjusted dose. All plasma concentrations in infants were under the quantitation limit (0.4 ng/mL). CONCLUSION Infant exposure to amlodipine in breast milk appears very small, suggesting that amlodipine can be used with little influence on infants during breastfeeding.


Case Reports in Perinatal Medicine | 2015

Management of fetal ovarian cyst using in utero aspiration

Seung Chik Jwa; Hiroaki Aoki; Ai Anami; Nagayoshi Umehara; Masahiro Sumie; Seiji Wada; Haruhiko Sago

Abstract Objective: To study the clinical outcome of fetal ovarian cysts managed with in utero aspiration. Methods: All cases of fetal ovarian cysts diagnosed from 2002 to 2013 were reviewed. In utero aspiration was performed for patients with simple cysts larger than 4 cm before term gestation. Results: There were 21 cases of fetal ovarian cysts. Four patients (19%) were diagnosed with complex cysts at the time of referral. Among the 17 cases of simple cysts, in utero aspiration was performed in seven patients. There were no complications after the therapy and none of them developed complex cysts. An ovarian cyst was confirmed by cyst fluid that contained high levels of estradiol, progesterone and testosterone. For two patients with simple cysts who met the indications for in utero aspiration but did not receive therapy, one developed a complex cyst. Among the eight patients with simple cysts who did not fulfill the indications for aspiration, seven of them had cysts that regressed spontaneously, and one developed complex cysts during pregnancy. Conclusion: Torsion of fetal ovarian cysts was common with expectant management. Management of fetal ovarian cysts larger than 4 cm using in utero aspiration may avoid torsion, which could otherwise lead to ovarian loss.

Collaboration


Dive into the Hiroaki Aoki's collaboration.

Top Co-Authors

Avatar

Aikou Okamoto

Jikei University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Katsuhiko Yanaga

Jikei University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Osamu Samura

Jikei University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Tomohiro Tanemoto

Jikei University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Taisuke Sato

Jikei University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Nobuo Omura

Jikei University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Norio Mitsumori

Jikei University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Atsuo Shida

Jikei University School of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kazuhiro Kajiwara

Jikei University School of Medicine

View shared research outputs
Researchain Logo
Decentralizing Knowledge